Retatrutide Explained: The Triple Receptor Agonist

Retatrutide activates three receptors with one molecule: GIP, GLP-1 and glucagon. It is the first of the triple agonists to reach large scale human trials, and the third receptor is the part worth understanding, because on the face of it adding glucagon looks like a mistake.

The background on how GLP-1 works and on tirzepatide covers the first two receptors. This picks up from there.

Why adding glucagon sounds backwards

Glucagon is the hormone that raises blood glucose. When glucose drops, the pancreas releases glucagon, the liver breaks down stored glycogen and pushes glucose into the blood. GLP-1 does the opposite, suppressing glucagon release.

So a molecule designed to control glucose that also switches on the glucagon receptor seems to be arguing with itself. The resolution is that glucagon does more than one job.

The other side of glucagon

Glucagon receptor activation increases energy expenditure. It also drives fat breakdown in the liver, pushing hepatocytes toward burning fatty acids rather than storing them.

Those are useful effects, and they are separate from the glucose raising one. The design bet behind retatrutide is that you can keep the metabolic effects of glucagon while the GLP-1 and GIP arms handle glucose control, so the glucose raising tendency is offset within the same molecule.

That gives you two distinct mechanisms working on body weight at once. The incretin arms reduce how much energy comes in, largely through appetite and slowed gastric emptying. The glucagon arm raises how much energy goes out. Compounds that only hit GLP-1, or GLP-1 and GIP, work almost entirely on the intake side.

How it is built

Retatrutide follows the same engineering playbook as tirzepatide.

The backbone is based on the GIP sequence, modified until it fits all three receptors. Non standard amino acids sit at the positions where DPP-4 would normally cut the molecule apart, which removes the two minute half life problem that native incretins have.

A fatty acid chain is attached so the peptide binds reversibly to albumin in the blood. Bound to albumin it is shielded from enzymes, too large for the kidneys to filter, and released gradually. That is what turns it into a once weekly compound rather than something that disappears in minutes.

What the trials found

Retatrutide was tested in a phase 2 trial in adults with obesity, published in 2023. Participants received weekly doses for 48 weeks across several dose levels.

At the highest dose studied, 12 mg weekly, mean weight reduction from baseline was about 24.2% at 48 weeks. The effect scaled with dose across the groups, and the curve had not flattened by the end of the trial period.

Gastrointestinal effects were the ones most often reported, mainly nausea, diarrhea and vomiting, concentrated around dose increases. Heart rate increases were also recorded, which is consistent with glucagon receptor activation raising energy expenditure.

Separate work has looked at retatrutide in type 2 diabetes and in fatty liver disease, the latter being a natural fit given what glucagon receptor activation does to hepatic fat.

Where it sits against the others

Compound	Receptors	Main levers
Semaglutide class	GLP-1	Appetite, gastric emptying, insulin
Tirzepatide	GIP + GLP-1	The above, plus GIP signaling in fat and brain
Retatrutide	GIP + GLP-1 + glucagon	The above, plus energy expenditure and liver fat

Each generation adds a receptor rather than replacing one. That is the through line of this entire class.

Handling notes

Retatrutide is supplied freeze dried and needs mixing. The usual rules apply: bring the vial to room temperature first, run the water down the inside wall rather than firing it into the powder, and do not shake it. The reconstitution guide has the full sequence, and storage matters once it is in solution.

Stocked here in 5 mg, 10 mg, 20 mg, 30 mg, 40 mg and 60 mg vials.

Common questions

What does triple agonist mean?

One molecule that binds and activates three separate receptor types. Retatrutide activates the GIP, GLP-1 and glucagon receptors, so a single compound produces effects that would otherwise require three.

How is it different from tirzepatide?

Tirzepatide hits two receptors, GIP and GLP-1, and works mainly on the energy intake side. Retatrutide adds the glucagon receptor, which brings energy expenditure and liver fat metabolism into the picture.

Why does heart rate come up in the trial data?

Glucagon receptor activation increases energy expenditure, and a rise in metabolic rate is generally accompanied by a rise in heart rate. It follows directly from the mechanism.

Why weekly dosing?

The fatty acid chain binds albumin, which protects the peptide from breakdown and releases it slowly over days. Without that modification the molecule would be cleared within minutes.

TL;DR

Retatrutide is a single acylated peptide that activates the GIP, GLP-1 and glucagon receptors. The incretin arms reduce energy intake while the glucagon arm raises energy expenditure and drives fat breakdown in the liver. In a 48 week phase 2 trial, the 12 mg weekly dose produced mean weight reduction of about 24.2%.

Everything we supply is lab tested for purity and identity, and sold as research grade material for laboratory and research use. See the full GLP-1 and weight management range.

Featured image by IAEA Imagebank, CC BY 2.0.